Alfuzosin for the management of benign prostate hyperplasia

Author： Weiner David M   Lowe Franklin C  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.11, 2003-11, pp. : 2057-2063

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia: a Randomized Controlled Clinical Trial

By Lapitan MCM   Acepcion V   Mangubat J  

The Journal of International Medical Research, Vol. 33, Iss. 5, 2005-09 ,pp. : 562-573

Field House Publishing

Access to resources Recommend Favorite

Alfuzosin: A Review of the Therapeutic Use of the Prolonged-Release Formulation Given Once Daily in the Management of Benign Prostatic Hyperplasia

By McKeage K.   Plosker G.L.  

Drugs, Vol. 62, Iss. 4, 2002-04 ,pp. : 633-653

Adis International

Access to resources Recommend Favorite

Alfuzosin: an α1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

By Elhilali Mostafa M  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 583-596

Informa Healthcare

Access to resources Recommend Favorite

Doxazosin and alfuzosin have similar efficacy in improving obstructive symptoms associated with benign prostatic hyperplasia

By  

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Effect of Once-Daily Alfuzosin on Urinary Symptoms and Flow Rate in Benign Prostatic Hyperplasia: A 24-Hour Home-Uroflowmetry Evaluation

By Cosimo De Nunzio   Franco Giorgio   Leonardo Costantino   Trucchi Alberto   Tubaro Andrea   Laurenti Cesare  

Clinical Drug Investigation, Vol. 25, Iss. 6, 2005-01 ,pp. : 359-365

Adis International

Access to resources Recommend Favorite